Pancreatic Cancer Screening Using the Enzeavour Assay in Japan

Pancreatic Cancer Screening Using Single-Molecule Enzyme Activity-Based Liquid Biopsy, Enzeavour: A Single-Arm Interventional Feasibility Study Protocol in Japan - ENZEAVOUR Feasibility Study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000059647

Enrollment

10000

Registered

2025-11-05

Start date

2025-12-25

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer, Pancreatic neoplasms

Interventions

Primary screening will use the Enzeavour Pancreatic Cancer Test. Secondary screening will use diagnostic imaging (MRI/MRCP, EUS, or contrast-enhanced CT), selected at the investigator&#39

s discretion for each participant.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Asymptomatic adults attending participating facilities for routine health checkups, organized cancer screening, or both - Able to understand the study procedures and provide written informed consent before enrollment

Exclusion criteria

Exclusion criteria: - Documented clinical history of pancreatic cancer - Considered unable or unwilling to undergo any required diagnostic imaging modality (MRCP, EUS, or contrast-enhanced CT) after a positive index test result - Any medical, psychological, or social condition that, in the opinion of the principal investigator at each participating site, makes participation inappropriate or compromises study integrity

Design outcomes

Primary

Measure	Time frame
Pancreatic Cancer Detection Rate	—

Secondary

Measure	Time frame
Positive Predictive Value of the Enzeavour Assay	—

Countries

Japan

Contacts

Public ContactYu Kagami

Cosomil Inc. CEO

f-study@cosomil.com03-6823-2260

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026